Literature DB >> 14677644

Ultrastructure of mouse striated muscle fibers following pravastatin administration.

Michael Bergman1, Hertzel Salman, Meir Djaldetti, Svetlana Alexandrova, Igor Punsky, Hanna Bessler.   

Abstract

To examine the effect of pravastatin administration on striated muscle ultrastructure, 10 BalbC mice were given pravastatin 40 mg/kg/day for 3 weeks. At the end of the study, blood was withdrawn for evaluation of the serum creatine phospho-kinase (CPK) level and the muscles of the hind legs, as well as the heart and liver of the animals were examined with a light and transmission electron microscope. After treatment with pravastatin the results showed a 101% increase in serum CPK level in comparison to untreated controls. Hematoxillin-eosin stained tissues of pravastatin treated mice did not show any abnormal findings. While the ultrastructure of the heart and liver of the treated animals appeared normal, the muscle fibers showed a marked alterations of the mitochondria, which were increased in size compared to those of the controls. The cristae were heavily damaged and even completely destructed, giving the mitochondria appearance of empty vacuoles. The findings are in favor of a specificity of pravastatin for striated muscles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677644     DOI: 10.1023/a:1027367022415

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  20 in total

1.  HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.

Authors:  O P Flint; B A Masters; R E Gregg; S K Durham
Journal:  Toxicol Appl Pharmacol       Date:  1997-07       Impact factor: 4.219

2.  Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.

Authors:  S A Mortensen; A Leth; E Agner; M Rohde
Journal:  Mol Aspects Med       Date:  1997

3.  Lovastatin decreases coenzyme Q levels in humans.

Authors:  K Folkers; P Langsjoen; R Willis; P Richardson; L J Xia; C Q Ye; H Tamagawa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.

Authors:  B A Masters; M J Palmoski; O P Flint; R E Gregg; D Wang-Iverson; S K Durham
Journal:  Toxicol Appl Pharmacol       Date:  1995-03       Impact factor: 4.219

5.  Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.

Authors:  M Fukami; N Maeda; J Fukushige; Y Kogure; Y Shimada; T Ogawa; Y Tsujita
Journal:  Res Exp Med (Berl)       Date:  1993

6.  HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.

Authors:  P F Smith; R S Eydelloth; S J Grossman; R J Stubbs; M S Schwartz; J I Germershausen; K P Vyas; P H Kari; J S MacDonald
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

Review 7.  [Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase].

Authors:  E Decoulx; A Millaire; P de Groote; G Mahieux; G Ducloux
Journal:  Ann Cardiol Angeiol (Paris)       Date:  1993-05

8.  Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.

Authors:  K Nakahara; M Kuriyama; Y Sonoda; H Yoshidome; H Nakagawa; J Fujiyama; I Higuchi; M Osame
Journal:  Toxicol Appl Pharmacol       Date:  1998-09       Impact factor: 4.219

9.  Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.

Authors:  S Pierno; A De Luca; D Tricarico; A Roselli; F Natuzzi; E Ferrannini; M Laico; D C Camerino
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

10.  Pravastatin-associated myopathy. Report of a case.

Authors:  T Scalvini; D Marocolo; B Cerudelli; I Sleiman; G P Balestrieri; G Giustina
Journal:  Recenti Prog Med       Date:  1995-05
View more
  3 in total

1.  Biphasic regulation of intracellular calcium by gemfibrozil contributes to inhibiting L6 myoblast differentiation: implications for clinical myotoxicity.

Authors:  Aiming Liu; Julin Yang; Frank J Gonzalez; Gary Q Cheng; Renke Dai
Journal:  Chem Res Toxicol       Date:  2010-12-22       Impact factor: 3.739

2.  Curcumin improves atorvastatin-induced myotoxicity in rats: Histopathological and biochemical evidence.

Authors:  Said Said Elshama; Ayman El-Meghawry El-Kenawy; Hosam-Eldin Hussein Osman
Journal:  Int J Immunopathol Pharmacol       Date:  2016-08-09       Impact factor: 3.219

3.  Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity.

Authors:  Sylvie Callegari; Philip A Gregory; Matthew J Sykes; Jennifer Bellon; Stuart Andrews; Ross A McKinnon; Miguel A de Barros Lopes
Journal:  PLoS Genet       Date:  2012-06-14       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.